Related Experiment Videos
[Flow cytometry in cancer of the bladder]
A Chassevent1, Y M Allain, D Chautard
1Centre Paul-Papin, Angers, France.
Summary
DNA flow cytometry is valuable for monitoring bladder cancer, especially carcinoma in situ and superficial tumors. Its findings, like DNA aneuploidy, correlate with tumor stage and grade, aiding in treatment resistance assessment.
Area of Science:
- Uro-oncology
- Molecular pathology
- Diagnostic cytometry
Context:
- DNA flow cytometry (FCM) is a technique used to analyze DNA content in cells.
- Its application in bladder cancer diagnosis and management requires careful consideration of technical aspects and clinical context.
- Current validation relies on parametric analysis of tumor cell DNA content across multiple biopsies.
Purpose:
- To reassess the utility of DNA flow cytometry in bladder cancer management.
- To discuss the technical factors influencing the validity of DNA FCM results.
- To examine the complementary role of bladder washings and biopsies in conjunction with FCM.
Summary:
- DNA FCM results, particularly DNA aneuploidy, show a significant correlation with bladder tumor grade and stage.
- Complementary analyses of bladder washings and biopsies enhance diagnostic accuracy.
- While not for screening, DNA FCM is crucial for monitoring carcinoma in situ and stratifying superficial tumors.
Impact:
- Clinical interpretation of DNA FCM requires caution, with a consensus against its use in screening.
- DNA FCM is particularly useful for follow-up of carcinoma in situ, where DNA aneuploidy is consistently observed.
- In invasive tumors, persistent or emerging DNA aneuploidy may indicate therapeutic resistance, guiding treatment strategies.